Background Bereavement support models have been challenged during recent years, with less opportunity for individual face-to-face support. Walk and talk groups are inclusive and combine the benefits ...
Background Since 2015 LOROS has been using the Integrated Palliative Outcome Score (IPOS) in our clinical services. We present how we use IPOS data in our MDT meetings and feed back to clinical ...
Correspondence to Dr Farzana Virani, Palliative Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7JX, UK; farzana.virani{at}nhs.net There remains uncertainty regarding the ...
Palliative care for adults with neuromuscular conditions is an emerging field. Previous guidelines regarding myotonic dystrophy and palliative care have only mentioned end-of-life care and little else ...
Background Controlled drugs (CDs) such as opioids and midazolam are commonly used in end-of-life care symptom management for care home residents. Aim To review the published evidence concerning the ...
Background Palliative care (PC) refers to providing patients with physical, psychological, mental, and other care and humanistic care services in a multidisciplinary collaborative mode with ...
Background Natural disasters are becoming more frequent and severe, and place additional strains on end-of-life care services and users. Although end-of-life and palliative care are considered ...
Background Acupuncture has been demonstrated to be a safe and effective treatment for insomnia in patients without cancer. A lack of evidence, however, supports its application in the treatment of ...
Correspondence to Stefaan Six, Public Health, Vrije Universiteit Brussel - Brussels Health Campus, Brussel 1090, Belgium; stefaan.six{at}vub.be Palliative care is increasingly confronted with cultural ...
Objectives Breathlessness affects a significant proportion of patients in palliative care. This Quality Improvement Project aimed to develop a patient self-management resource, Living with ...
Objective Osimertinib plays a crucial role in patients with non-small cell lung cancer (NSCLC). However, the haematological toxicities caused by osimertinib in such a population have not been well ...